Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Italy

European Research Council grant · Running

CO-TRANS-NET Synthetic nucleic acid co-transcriptional networks as diagnostic and therapeutic tools

Coordinator
Universita Degli Studi Di Roma Tor Vergata, Italy
Runs
1 January 2025 to 31 December 2029
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101165168

What the project is doing

In the project's own words, from its summary on CORDIS.

WHY: The heterogeneity of tumors often makes their diagnosis and treatment a very hard task. A single tumor can have many different diagnostically-relevant molecular markers which can also be used to monitor the efficacy of treatment. Innovative, simple, cost-effective, and quantitative analytical tools for diagnostic and therapeutic applications are urgently needed to ensure rapid and appropriate patient care. WHAT: CO-TRANS-NET project addresses this need by developing synthetic nucleic acid units that can respond to a wide range of tumor biomarkers and can provide innovative tools for biosensing and therapeutics through cell-free in-vitro transcription.

HOW: The ground-breaking idea of CO-TRANS-NET is to harness the high programmability of synthetic nucleic acids together with the high sensitivity and versatility of cell-free systems to develop co-transcriptional networks that, in one pot, through nature-inspired recognition mechanisms, can respond to a variety of targets including proteins, small molecules and antibodies and trigger in-vitro transcription of functional RNA.

The transcribed RNA can provide a measurable signal or produce a therapeutic drug. CO-TRANS-NET aims to develop single theranostic nanodevices in which cancer diagnosis and theraphy can be simultaneously achieved- This goes beyond the state of the art and represents a breakthrough in the field of diagnostics, biosensing, synthetic biology and nucleic acid-based therapeutics.

Topics

Who is involved

OrganisationCityCountryRole
Universita Degli Studi Di Roma Tor VergataRomaItalyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI